The abstract is read at the publisher; the summary is JClub's.
ASCO’s living guideline for systemic therapy in metastatic castration-resistant prostate cancer is continuously updated to reflect rapidly changing evidence and clinical practice needs.
- Why it matters: Evidence in this setting evolves quickly, creating a gap between emerging data and stable recommendations for clinicians.
- What they did: A standing expert panel systematically reviews the health literature on an ongoing basis and issues scheduled updates under ASCO’s living guideline methodology and conflict-of-interest policy.
- The result: The guideline and its updates provide current recommendations while explicitly not replacing clinician judgment or accounting for individual patient variation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.